Clinical Trial Update: A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms [Phase 2]

View source ↗

Summary

Phase II study of SGI-110 in Philadelphia-negative myeloproliferative neoplasms completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myeloproliferative Neoplasms

Drugs mentioned

• SGI-110 (guadecitabine)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Myeloproliferative Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2022-04-06